Antisense Therapeutics Limited (ATHJF)
USD 0.01
(-76.0%)
USD 0.01
(-76.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.11 Million | -8.15 Million | -7.8 Million | -5.83 Million | -3.94 Million | -2.92 Million |
| Net Income | -11.91 Million | -11.37 Million | -5.81 Million | -8.06 Million | -5.9 Million | -2.94 Million |
| Depreciation & Amortization | 79.42 Thousand | 95.19 Thousand | 89.21 Thousand | 103.31 Thousand | 107.6 Thousand | 5377.00 |
| Deferred income taxes | - | -214.05 Thousand | -124.41 Thousand | -1.37 Million | -2.42 Million | - |
| Stock-based compensation | 198.39 Thousand | 214.05 Thousand | 124.41 Thousand | 1.37 Million | 2.42 Million | - |
| Change in working capital | 1.52 Million | 2.87 Million | -2.2 Million | 756.72 Thousand | -564.84 Thousand | 10.68 Thousand |
| Other non-cash items | -1.19 Million | 262.8 Thousand | 124.41 Thousand | 1.36 Million | 2.42 Million | 67.19 Thousand |
| Investing Cash Flow | -3606.00 | -29.29 Thousand | -3913.00 | -8349.00 | -10.26 Thousand | 2.4 Million |
| Investments in PPE | -3606.00 | -29.29 Thousand | -3913.00 | -8349.00 | -10.26 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | 2.4 Million |
| Sales/Maturities of investments | - | - | - | - | - | 2.4 Million |
| Other Investing Activities | - | - | - | - | - | -2.4 Million |
| Financing Cash Flow | 11.01 Million | -85.3 Thousand | 21.02 Million | 7.8 Million | 5.11 Million | 1.53 Million |
| Debt repayment | -89.38 Thousand | -85.3 Thousand | -79.44 Thousand | -82.38 Thousand | -97.89 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -503.27 Thousand | - | -1.48 Million | -614.14 Thousand | -285.15 Thousand | -67.08 Thousand |
| Common Stock Issuance | 11.1 Million | - | 22.58 Million | 8.5 Million | 5.49 Million | 1.6 Million |
| Other Financing Activities | -89.38 Thousand | -85.3 Thousand | -79.44 Thousand | -82.38 Thousand | -97.89 Thousand | 1.53 Million |
| Accounts receivables | -832.35 Thousand | 341.48 Thousand | -1.23 Million | 88.06 Thousand | -339.76 Thousand | -275.3 Thousand |
| Accounts payables | 2.38 Million | 1.76 Million | 28.94 Thousand | 220.4 Thousand | -259.8 Thousand | 218.86 Thousand |
| Inventory | - | - | - | - | -1.00 | - |
| Other working capital | -24.3 Thousand | 768.04 Thousand | -996.2 Thousand | 448.25 Thousand | 34.73 Thousand | 67.12 Thousand |
| Cash at beginning of period | 10.96 Million | 19.23 Million | 6.02 Million | 4.05 Million | 2.9 Million | 1.89 Million |
| Cash at end of period | 11.86 Million | 10.96 Million | 19.23 Million | 6.02 Million | 4.05 Million | 2.9 Million |
| Capital Expenditure | -3606.00 | -29.29 Thousand | -3913.00 | -8349.00 | -10.26 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 899.4 Thousand | -8.26 Million | 13.21 Million | 1.96 Million | 1.15 Million | 1 Million |
| Free Cash Flow | -10.11 Million | -8.18 Million | -7.8 Million | -5.84 Million | -3.95 Million | -2.92 Million |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -11.91 Million | -3.58 Million | -3.58 Million | -4.74 Million | -2.37 Million | -11.37 Million |
| Depreciation & Amortization | 79.42 Thousand | 16.01 Thousand | 16.01 Thousand | 47.4 Thousand | 23.7 Thousand | 95.19 Thousand |
| Deferred income taxes | - | - | - | - | - | -214.05 Thousand |
| Stock-based compensation | - | 45.26 Thousand | 45.26 Thousand | 53.93 Thousand | 53.93 Thousand | 214.05 Thousand |
| Change in working capital | 1.52 Million | -428.33 Thousand | -428.33 Thousand | - | - | 2.87 Million |
| Other non-cash items | -1.19 Million | 1.27 Million | 1.27 Million | -43.75 Thousand | -78.94 Thousand | 262.8 Thousand |
| Investing Cash Flow | -3606.00 | 1486.00 | 1486.00 | -6578.00 | -3289.00 | -29.29 Thousand |
| Investments in PPE | -3606.00 | 1486.00 | 1486.00 | -6578.00 | -3289.00 | -29.29 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 11.01 Million | 20.29 Thousand | 20.29 Thousand | 11.06 Million | 5.48 Million | -85.3 Thousand |
| Debt repayment | - | - | - | - | - | -85.3 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -503.27 Thousand | - | - | - | - | - |
| Common Stock Issuance | 11.1 Million | - | - | 11.1 Million | - | - |
| Other Financing Activities | -89.38 Thousand | 20.29 Thousand | 20.29 Thousand | 5.48 Million | 5.48 Million | -85.3 Thousand |
| Accounts receivables | -832.35 Thousand | -416.18 Thousand | -416.18 Thousand | - | - | 341.48 Thousand |
| Accounts payables | 2.38 Million | - | - | - | - | 1.76 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -24.3 Thousand | -12.15 Thousand | -12.15 Thousand | - | - | 768.04 Thousand |
| Cash at beginning of period | 10.96 Million | 17.19 Million | - | 10.96 Million | - | 19.23 Million |
| Cash at end of period | 11.86 Million | 11.86 Million | -2.66 Million | 17.19 Million | 3.11 Million | 10.96 Million |
| Capital Expenditure | -3606.00 | 1486.00 | 1486.00 | -6578.00 | -3289.00 | -29.29 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 899.4 Thousand | -5.32 Million | -2.66 Million | 6.22 Million | 3.11 Million | -8.26 Million |
| Free Cash Flow | -10.11 Million | -2.68 Million | -2.68 Million | -4.84 Million | -2.37 Million | -8.18 Million |
WLDS
JIN
0258
OPRX
APE
NVCR